Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Shares Outstanding (Weighted Average) (2024 - 2025)

Historic Shares Outstanding (Weighted Average) for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $76.1 million.

  • Prelude Therapeutics' Shares Outstanding (Weighted Average) rose 36.44% to $76.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.1 million, marking a year-over-year increase of 36.44%. This contributed to the annual value of $75.8 million for FY2024, which is N/A changed from last year.
  • Prelude Therapeutics' Shares Outstanding (Weighted Average) amounted to $76.1 million in Q3 2025, which was up 36.44% from $76.0 million recorded in Q2 2025.
  • Prelude Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $76.1 million during Q3 2025, with a 5-year trough of $75.7 million in Q1 2024.